[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341249-105":59,"doc-detail-341249-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nanotechnology-based-strategy-for-enhancing-therapeutic-efficacy-in-pancreatic-cancer-receptor-targeted-drug-delivery-by-somatostatin-analog-article","Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog - Article","","A novel nanotechnology-based drug delivery system targeted to pancreatic cancer cells was developed, characterized, and tested. The formulation used liposomes as carriers, paclitaxel as the chemotherapeutic agent, and a modified synthetic somatostatin analog, 5-pentacarbonyl-octreotide, as an SSTR2-targeting ligand. In vitro studies assessed cellular internalization, cytotoxicity, and antitumor effects in PDAC cells with differing SSTR2 levels, while in vivo testing used immunodeficient mice bearing human PDAC xenografts.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nanotechnology-based-strategy-for-enhancing-therapeutic-efficacy-in-pancreatic-cancer-receptor-targeted-drug-delivery-by-somatostatin-analog-article/341249/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nanotechnology-based-strategy-for-enhancing-therapeutic-efficacy-in-pancreatic-cancer-receptor-targeted-drug-delivery-by-somatostatin-analog-article/341249.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the core design of the nanotechnology-based drug delivery system for pancreatic cancer?","Question",{"text":112,"@type":113},"It combines liposomes as carriers, paclitaxel as the chemotherapeutic payload, and a modified somatostatin analog (5-pentacarbonyl-octreotide) that targets SSTR2.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the drug delivery system evaluated in vitro?",{"text":117,"@type":113},"Cellular internalization, cytotoxicity, and antitumor activity were tested using human PDAC cells with different SSTR2 receptor expression levels.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the targeted system perform in vivo?",{"text":121,"@type":113},"Octreotide-targeted liposomal delivery strongly suppressed the growth of PDAC tumors in immunodeficient mice bearing human PDAC xenografts.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341249,1790100601,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Article  \nNanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog  \nXin Gu 1, Joydeb Majumder 1, Olena Taratula 2, Andriy Kuzmov 1, Olga Garbuzenko 1, Natalia Pogrebnyak 1 and Tamara Minko 1,3, *  \nCitation: Gu, X.; Majumder, J.; Taratula, O.; Kuzmov, A.; Garbuzenko, O.; Pogrebnyak, N.; Minko, T. Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog. Int. J. Mol. Sci. 2024, 25, 5545 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25105545  \nAcademic Editors: Claudio Luchini and Donatella Delle Cave  \nReceived: 19 April 2024  \nRevised: 12 May 2024  \nAccepted: 16 May 2024  \nPublished: 19 May 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08554, USA  \n2 Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR 97201, USA  \n3 Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA  \n* [Correspondence: minko@pharmacy.rutgers.edu](Correspondence: minko@pharmacy.rutgers.edu); Tel.: +1-848-445-6348; Fax: +1-732-445-3133  \nAbstract: A novel nanotechnology-based drug delivery system (DDS) targeted at pancreatic cancer cells was developed, characterized, and tested. The system consisted of liposomes as carriers, an anticancer drug (paclitaxel) as a chemotherapeutic agent, and a modified synthetic somatostatin analog, 5-pentacarbonyl-octreotide, a ligand for somatostatin receptor 2 (SSTR2), as a targeting moiety for pancreatic cancer. The cellular internalization, cytotoxicity, and antitumor activity of the DDS were tested in vitro using human pancreatic ductal adenocarcinoma (PDAC) cells with different expressions of the targeted SSTR2 receptors, and in vivo on immunodeficient mice bearing human PDAC xenografts. The targeted drug delivery system containing paclitaxel exhibited significantly enhanced cytotoxicity compared to non-targeted DDS, and this efficacy was directly related to the levels of SSTR2 expression. It was found that octreotide-targeted DDS proved exceptionally effective in suppressing the growth of PDAC tumors. This study underscores the potential of octreotidetargeted liposomal delivery systems to enhance the therapeutic outcomes for PDAC compared with non-targeted liposomal DDS and Paclitaxel-Cremophor® EL, suggesting a promising avenue for future cancer therapy innovations.  \nKeywords: somatostatin receptor 2 (SSTR2); nanoparticle-based drugs; liposome; paclitaxel; targeted delivery system  \n1. Introduction  \nAccounting for 90% of all pancreatic malignancies, pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the United States, with a five-year survival rate of 8%[1] . Although surgery can be an effective way to treat PDAC, the statistical report suggests that 80% of pancreatic cancer cases are unresectable, and, in many cases, local recurrence can occur after tumor resection [2] . PDAC’s complexity is underscored by its genetic diversity, elevated interstitial fluid pressure, and thick tumorstroma, which contribute to a challenging microenvironment. These factors notably amplify its tendency to metastasize and resist drugs, making it difficult for conventional chemotherapy treatments to deliver therapeutic agents effectively [3–5] . Nanotechnology has risen as a critical field in tackling the complexities of diverse cancer types throu","cbCaitqlSZLZQg5Y","https://ap.wps.com/l/cbCaitqlSZLZQg5Y","pdf",4106978,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What is the core design of the nanotechnology-based drug delivery system for pancreatic cancer?\",\"answer\":\"It combines liposomes as carriers, paclitaxel as the chemotherapeutic payload, and a modified somatostatin analog (5-pentacarbonyl-octreotide) that targets SSTR2.\"},{\"question\":\"How was the drug delivery system evaluated in vitro?\",\"answer\":\"Cellular internalization, cytotoxicity, and antitumor activity were tested using human PDAC cells with different SSTR2 receptor expression levels.\"},{\"question\":\"How did the targeted system perform in vivo?\",\"answer\":\"Octreotide-targeted liposomal delivery strongly suppressed the growth of PDAC tumors in immunodeficient mice bearing human PDAC xenografts.\"}]","Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog - Article | PDF",1790041114,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fcd83a82362a3ec6736996d9816ead39.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/848e0a45f3aae797dd1a230d43dcc4a5.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a9f31e0e12ea7990233902f56123431.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01fec5467c7db5f9b7ca50752d1cf7bd.webp",980,1385]